 Theodore Alkousakis
Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 6 | 2019 | 855 | 1.250 |
Why?
| | Melanoma | 4 | 2019 | 760 | 1.130 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2018 | 94 | 1.120 |
Why?
| | Fluorouracil | 2 | 2018 | 208 | 1.070 |
Why?
| | Skin Diseases | 2 | 2018 | 149 | 1.010 |
Why?
| | Shiitake Mushrooms | 1 | 2021 | 2 | 0.740 |
Why?
| | Acute Generalized Exanthematous Pustulosis | 1 | 2021 | 4 | 0.740 |
Why?
| | Exanthema | 1 | 2021 | 78 | 0.690 |
Why?
| | Dermatologic Agents | 3 | 2025 | 70 | 0.680 |
Why?
| | Psoriasis | 3 | 2025 | 102 | 0.660 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2020 | 20 | 0.650 |
Why?
| | Ipilimumab | 1 | 2019 | 33 | 0.640 |
Why?
| | Alopecia Areata | 1 | 2019 | 13 | 0.640 |
Why?
| | Dermoscopy | 1 | 2018 | 10 | 0.580 |
Why?
| | Injections, Intralesional | 1 | 2018 | 34 | 0.580 |
Why?
| | Nevus, Pigmented | 1 | 2018 | 34 | 0.570 |
Why?
| | Photochemotherapy | 1 | 2018 | 44 | 0.560 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2018 | 89 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.550 |
Why?
| | Mitosis | 1 | 2018 | 192 | 0.520 |
Why?
| | Travel | 1 | 2017 | 130 | 0.520 |
Why?
| | Laser Therapy | 1 | 2018 | 130 | 0.500 |
Why?
| | Academic Medical Centers | 1 | 2017 | 512 | 0.450 |
Why?
| | Anxiety | 1 | 2020 | 1035 | 0.390 |
Why?
| | Head and Neck Neoplasms | 1 | 2018 | 606 | 0.390 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 804 | 0.360 |
Why?
| | Skin Pigmentation | 3 | 2025 | 49 | 0.350 |
Why?
| | Aged, 80 and over | 6 | 2019 | 7635 | 0.280 |
Why?
| | Scalp Dermatoses | 1 | 2025 | 3 | 0.240 |
Why?
| | Patient Selection | 1 | 2025 | 696 | 0.170 |
Why?
| | Mind-Body Therapies | 1 | 2020 | 7 | 0.170 |
Why?
| | Hypnosis | 1 | 2020 | 11 | 0.160 |
Why?
| | Motion Pictures | 1 | 2020 | 19 | 0.160 |
Why?
| | Music | 1 | 2020 | 43 | 0.160 |
Why?
| | Prognosis | 2 | 2018 | 4030 | 0.150 |
Why?
| | Humans | 15 | 2025 | 137585 | 0.150 |
Why?
| | Mitotic Index | 1 | 2018 | 25 | 0.150 |
Why?
| | Cicatrix, Hypertrophic | 1 | 2018 | 1 | 0.150 |
Why?
| | Skin Ulcer | 1 | 2018 | 14 | 0.140 |
Why?
| | Drug Eruptions | 1 | 2017 | 27 | 0.140 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2017 | 18 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.140 |
Why?
| | Middle Aged | 7 | 2025 | 33479 | 0.140 |
Why?
| | Biopsy, Needle | 1 | 2018 | 189 | 0.140 |
Why?
| | Area Under Curve | 1 | 2018 | 314 | 0.140 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 2017 | 8 | 0.130 |
Why?
| | Male | 11 | 2025 | 67762 | 0.130 |
Why?
| | Upper Extremity | 1 | 2018 | 99 | 0.130 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 183 | 0.130 |
Why?
| | Adult | 8 | 2025 | 37929 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1477 | 0.130 |
Why?
| | ROC Curve | 1 | 2018 | 554 | 0.130 |
Why?
| | Quality Improvement | 1 | 2025 | 1178 | 0.130 |
Why?
| | Heparin | 1 | 2017 | 261 | 0.120 |
Why?
| | Retrospective Studies | 3 | 2018 | 15657 | 0.120 |
Why?
| | Patient Satisfaction | 1 | 2020 | 660 | 0.120 |
Why?
| | Aged | 4 | 2018 | 23961 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2020 | 766 | 0.110 |
Why?
| | Pain | 1 | 2020 | 756 | 0.110 |
Why?
| | Leishmania major | 1 | 2014 | 8 | 0.110 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2014 | 14 | 0.110 |
Why?
| | Lower Extremity | 1 | 2018 | 427 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1483 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1738 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1946 | 0.100 |
Why?
| | Hemorrhage | 1 | 2017 | 722 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2828 | 0.100 |
Why?
| | Anticoagulants | 1 | 2017 | 664 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.100 |
Why?
| | Female | 8 | 2025 | 73304 | 0.090 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2025 | 1993 | 0.080 |
Why?
| | Quality of Life | 3 | 2025 | 2892 | 0.080 |
Why?
| | Adolescent | 2 | 2018 | 21513 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 5742 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 544 | 0.070 |
Why?
| | Scalp | 1 | 2025 | 35 | 0.060 |
Why?
| | Risk Factors | 2 | 2017 | 10388 | 0.060 |
Why?
| | Canada | 1 | 2025 | 418 | 0.050 |
Why?
| | Fasciotomy | 1 | 2003 | 12 | 0.050 |
Why?
| | Surgical Wound Dehiscence | 1 | 2003 | 22 | 0.050 |
Why?
| | Young Adult | 2 | 2018 | 13209 | 0.050 |
Why?
| | Laparotomy | 1 | 2003 | 109 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 564 | 0.050 |
Why?
| | Abdominal Injuries | 1 | 2003 | 123 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2025 | 10811 | 0.040 |
Why?
| | United States | 2 | 2025 | 14841 | 0.030 |
Why?
| | Sepsis | 1 | 2003 | 617 | 0.030 |
Why?
| | Mohs Surgery | 1 | 2017 | 27 | 0.030 |
Why?
| | Animals | 1 | 2018 | 36940 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2017 | 179 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Fluconazole | 1 | 2014 | 19 | 0.030 |
Why?
| | Aminoquinolines | 1 | 2014 | 19 | 0.030 |
Why?
| | Iraq | 1 | 2014 | 53 | 0.030 |
Why?
| | Cryotherapy | 1 | 2014 | 17 | 0.030 |
Why?
| | Arm | 1 | 2014 | 104 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2003 | 2654 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2014 | 255 | 0.020 |
Why?
| | Abdomen | 1 | 2003 | 125 | 0.010 |
Why?
| | Drainage | 1 | 2003 | 173 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2003 | 116 | 0.010 |
Why?
| | Postoperative Care | 1 | 2003 | 261 | 0.010 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 307 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2691 | 0.010 |
Why?
|
|
Alkousakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|